MALE Mamm Organoids

It is believed that the use of organoids derived from male breast tumors can be of fundamental support for the definition of the molecular mechanisms underlying the onset of the tumor. Furthermore, the development of such preclinical models could be of significant support for the identification of specific personalized and ad hoc therapeutic treatments for male pathology.

NCT Number	NCT06786663
Lead Sponsor	Regina Elena Cancer Institute Collaborators: San Giovanni Addolorata Hospital, Weizmann Institute of Science, Israel, S. Andrea Hospital
Conditions	Breast Neoplasms, Male
Enrollment	7 participants
Start Date	2024-04-19
Primary Completion	2027-04-19 (estimated)
Study Completion	2027-04-19 (estimated)
Updated on ClinicalTrials.gov	2025-01-22